No Data
Viking Therapeutics | 10-Q: Quarterly report
Viking Therapeutics Insiders Sold US$21m Of Shares Suggesting Hesitancy
Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss for Q1 2025
Viking Therapeutics Price Target Cut to $102.00/Share From $105.00 by Morgan Stanley
Viking Therapeutics Is Maintained at Overweight by Morgan Stanley
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Edwards Lifesciences (EW) and Viking Therapeutics (VKTX)